RCM
ATOS icon

Rotella Capital Management’s Atossa Therapeutics ATOS Stock Holding History

Rotella Capital Management’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-4
Closed -$20K – 434
2015
Q1 		$20K Buy
+4
New +$17.1K 0.02% 491

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CWM
Concert Wealth Management San Jose, California $24.7M AUM 14.91% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
FCCM
First City Capital Management Savannah, Georgia $206M AUM 26.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Rotella Capital Management's ATOS Position: Q2 2015 in Review

Rotella Capital Management sold out of Atossa Therapeutics (ATOS) in Q2 2015, closing a stake of 4 shares — an estimated $20K sold.

Rotella Capital Management first reported a position in ATOS in Q1 2015 and held it in 1 quarter. The position peaked at $20K in Q1 2015. 14 funds tracked by Wall St. Rank hold ATOS as of Q2 2015.

  • Rotella Capital Management reported no remaining Atossa Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Rotella Capital Management sold 4 Atossa Therapeutics shares in Q2 2015, an estimated $20K.
  • Rotella Capital Management first reported a position in Atossa Therapeutics in Q1 2015 and held it in 1 quarter.
  • Rotella Capital Management's Atossa Therapeutics position peaked at $20K in Q1 2015.
  • 14 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2015.

Based on Rotella Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.